The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study
Sorafenib in advanced clear-cell renal-cell carcinoma.
We conducted a phase 3, randomized, double-blind, placebo-controlled trial of sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, in patients with advanced clear-cell renal-cell carcinoma. ⋯ As compared with placebo, treatment with sorafenib prolongs progression-free survival in patients with advanced clear-cell renal-cell carcinoma in whom previous therapy has failed; however, treatment is associated with increased toxic effects. (ClinicalTrials.gov number, NCT00073307 [ClinicalTrials.gov].).
-
Case Reports Retracted Publication
Images in clinical medicine. Complication of central venous catheterization.